The Wall Street Journal @WSJ
Uptake for Aduhelm, the newest approved drug for Alzheimer’s disease, remained slow over the summer, and sales could be minimal through the end of the year, drugmaker Biogen said https://t.co/wJRayBMGYK — PolitiTweet.org
Created
Wed Oct 20 13:45:08 +0000 2021
Likes
36
Retweets
5
Source
SocialFlow
View Raw Data
JSON DataView on Twitter
Likely Available
The Wall Street Journal @WSJ
Uptake for Aduhelm, the newest approved drug for Alzheimer’s disease, remained slow over the summer, and sales could be minimal through the end of the year, drugmaker Biogen said https://t.co/wJRayBMGYK — PolitiTweet.org